These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 32284393)

  • 1. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
    Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
    J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
    Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
    Warnders FJ; Waaijer SJ; Pool M; Lub-de Hooge MN; Friedrich M; Terwisscha van Scheltinga AG; Deegen P; Stienen SK; Pieslor PC; Cheung HK; Kosterink JG; de Vries EG
    J Nucl Med; 2016 May; 57(5):812-7. PubMed ID: 26848172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
    Suurs FV; Lorenczewski G; Bailis JM; Stienen S; Friedrich M; Lee F; van der Vegt B; de Vries EGE; de Groot DA; Lub-de Hooge MN
    J Nucl Med; 2021 Apr; 62(12):1797-804. PubMed ID: 33931466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
    Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
    Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing
    Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
    Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1
    Hong R; Zhou Y; Tian X; Wang L; Wu X
    Int Immunopharmacol; 2018 Jan; 54():118-124. PubMed ID: 29128855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging of Radiolabeled Bispecific T-Cell Engager
    Waaijer SJH; Warnders FJ; Stienen S; Friedrich M; Sternjak A; Cheung HK; van Scheltinga AGTT; Schröder CP; de Vries EGE; Lub-de Hooge MN
    Clin Cancer Res; 2018 Oct; 24(20):4988-4996. PubMed ID: 29980531
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.
    Waaijer SJH; Suurs FV; Hau CS; Vrijland K; de Visser KE; de Groot DJA; de Vries EGE; Lub-de Hooge MN; Schröder CP
    Front Oncol; 2021; 11():786191. PubMed ID: 34976826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
    Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
    J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4
    Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
    Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
    Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
    Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
    Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
    Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of
    Stergiou N; Wuensche TE; Schreurs M; Mes I; Verlaan M; Kooijman EJM; Windhorst AD; Helboe L; Vergo S; Christensen S; Asuni AA; Jensen A; Van Dongen GAMS; Bang-Andersen B; Vugts DJ; Beaino W
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1306-1317. PubMed ID: 36635462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors.
    Beckford Vera DR; Smith CC; Bixby LM; Glatt DM; Dunn SS; Saito R; Kim WY; Serody JS; Vincent BG; Parrott MC
    PLoS One; 2018; 13(3):e0193832. PubMed ID: 29513764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.